Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Get the latest on stock upgrades & downgrades, tariff impacts, and sector insights. From Apple to Tesla, discover key market ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and Company (NYSE:LLY). Its median price target of $736.93 implies an upside of 37.73 ...

Eli Lilly’s stock took a 4.6% dive after Morgan Stanley gently tapped the brakes on its optimism, lowering its price target ...

Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.

Eli Lilly shares stumbled 4.2% mid-Wednesday after Morgan Stanley clipped its price target, dropping investor spirits faster ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...